The protein-shredding revolution: Why Arvinas gave away the keys to its historic FDA approval

For years, a tantalizing premise has hovered over the biotech industry: what if, instead of merely blocking disease-causing proteins, we could hack the human body's own trash disposal system to shred them completely? In May 2026, that sci-fi concept—known as PROTAC—finally transitioned from theoretical marvel to approved medicine. The U.S. Food and Drug Administration officially cleared Arvinas’s VEPPANU, making it the first targeted protein degrader to ever cross the regulatory finish line. It is a landmark victory that fundamentally rewrites the rules for biological targets long dismissed as entirely undruggable.

But the aftermath of this scientific triumph tells a much starker story about the brutal economics of modern drug development. Inventing a revolutionary therapy is one thing; building the commercial infrastructure to actually sell it is an entirely different battle. Sensing the immense financial friction ahead, Arvinas and its heavyweight partner, Pfizer, made a pragmatic, if painful, calculation. Months before the FDA's green light, Arvinas initiated a harsh 15 percent workforce reduction, methodically stripping away its commercialization teams to brace for a strategic pivot away from the sales floor.

The culmination of that pivot arrived on May 12, scarcely two weeks post-approval, when Arvinas and Pfizer officially handed the global rights for VEPPANU over to Rigel Pharmaceuticals. Unburdened by the crushing costs of a market launch—which showed up in a softer-than-expected USD 15.6 million revenue print for the first quarter of 2026—Arvinas is now retreating to what it does best. Under the fresh leadership of CEO Randy Teel, the company is refocusing its capital on a deep pipeline of neurological and oncological moonshots, including a promising Parkinson's candidate. It is a vivid reminder that in today's biotech landscape, survival often means knowing exactly when to let go of your biggest breakthrough.